ライフサイエンスコーパス: i.n.

1 In addition, i.n. vaccination with PspA and IL-12 provided increased

2 onger Th2 responses following the additional i.n. administration of CT compared to i.n. or i.m. gB DN

3 Additionally, i.n. immunization elicited a stronger neutralizing serum

4 f Y. pestis in mice when it was administered i.n. but actually reduced the 50% lethal dose (LD(50)) b

5 ach peptide with LT(R192G) were administered i.n. to BALB/c mice.

6 g rNV VLPs are immunogenic when administered i.n. in the absence of adjuvant, and addition of adjuvan

7 ed of alveolar macrophages when administered i.n. P. aeruginosa.

8 In addition, after i.n. challenge with type 14 pneumococci, vaccinated mice

9 tion of antigen-specific B and T cells after i.n. immunization, antibody-secreting cells and antigen-

10 found especially in central CLN 2 days after i.n. immunization and persisted for up to 6 months, wher

11 nd then from the brain for 3 to 4 days after i.n. immunization.

12 2(-/-) mice died significantly earlier after i.n. infection.

13 presence of bacteria in blood 1 to 3 h after i.n. inoculation was sometimes observed, this was infreq

14 prolonged the survival of treated mice after i.n. F. tularensis challenge relative to mock treated an

15 a mucosal IgA immune response in mice after i.n. immunization supports their use as subunit vaccine

16 B-cell-deficient than in C57BL/6 mice after i.n. inoculation.

17 increased survival of neutropenic mice after i.n. P. aeruginosa inoculation.

18 intranasally (i.n.) with S. pneumoniae after i.n. administration of IL-12.

19 significant OVA-specific CTL responses after i.n. coadministration of LT with OVA or OVA257-264.

20 significantly protected (100% survival after i.n. immunization).

21 ter p.o. immunization was greater than after i.n. administration (means, 6.0 and 1.02 ng/ml, respecti

22 Therefore, after i.n. immunization, superficial and central CLN represent

23 testinal and systemic lymphoid tissues after i.n. inoculation with two or three doses of 2/6-VLPs wit

24 Protection against i.n. challenge of C57BL/6 mice was evaluated by vaccinat

25 Although i.n. DNA immunization was an effective means of inducing

26 Furthermore, although i.n. and i.v.-immunized mice had comparable levels of ch

27 mmunodeficient (SCID) C.B-17 mice against an i.n. challenge.

28 In unimmunized mice, an i.n. challenge with vSC8 caused a significant but self-l

29 ollowing vaccination, each group received an i.n. challenge of P. multocida.

30 the MVA prime/i.n. boost regimen received an i.n./i.m. combined C.1086 gp120 boost.

31 t with anti-CD3epsilon-specific antibody and i.n. proinsulin peptide can reverse recent-onset diabete

32 generated by intramuscular (i.m.) gB DNA and i.n. live HSV administration.

33 ference between the responses after o.g. and i.n. administration was even more remarkable.

34 th of time between influenza A infection and i.n. exposure to OVA was crucial, because mice exposed t

35 host resistance to primary LVS infection and i.n. secondary challenge.

36 In addition, both i.m. and i.n. plasmid immunizations failed to generate an immune

37 d a greater IgG Ab response in both i.p. and i.n. immunized mice and a greater IgA Ab response in muc

38 sal (i.n.) at a low dose and low volume, and i.n. at a high dose and high volume.

39 Rabbits vaccinated with both antigens i.n. or s.c. had a 100% survival rate, few or no bacteri

40 efficacy of administration of these antigens i.n. versus s.c.

41 detected beginning at 3 days p.i. from both i.n.- and i.p.-challenged animals.

42 ) routes are challenged with the allergen by i.n. administration.

43 and these responses were further boosted by i.n. delivery of M.85A.

44 s.c. inoculation but no virulence change by i.n. inoculation in mice.

45 ificantly elevated compared with controls by i.n. delivery of 100 microgram sIL-4R; i.p. delivery of

46 ite neutralizing antibody can be elicited by i.n. immunization with a flagellin-modified P. falciparu

47 ent influenza A virus infection, followed by i.n. inoculation with S. pneumoniae.

48 The immune responses generated by i.n. administration of gB DNA with or without cholera to

49 , mucosal and systemic antibodies induced by i.n. immunization persisted for at least 12 months.

50 To test whether CTL induced by i.n. immunization with OVA peptide and CT were functiona

51 unable to establish respiratory infection by i.n. inoculation.

52 are the dominant T cells induced in NALT by i.n. infections.

53 low volume and was completely preventable by i.n. vaccination of an attenuated virus at a low dose an

54 cosal immune responses, lung DC targeting by i.n. immunization induced protective immunity against en

55 1 h before or after Schu 4 or LVS (100 CFU) i.n. challenge showed that poly(I:C) treatment significa

56 the last immunization, mice were challenged i.n. with 10(4) inclusion-forming units (IFU) of C. muri

57 the last immunization, mice were challenged i.n. with 10(4) inclusion-forming units (IFU) of the C.

58 Combined i.n.-parenteral immunization of ferrets with maternal an

59 ory sequence oligodeoxynucleotide conjugate, i.n. and i.d. IT delivery were similarly effective in mo

60 In contrast, i.n. immunization was substantially more effective at in

61 concerned that Salmonella bacteria delivered i.n. might access the brain.

62 Immunization by OMV delivered i.n. was the only regimen that resulted in a serum bacte

63 portantly, mice immunized with LVS DeltacapB i.n. or i.d. and then challenged 6 weeks later by aeroso

64 Mice immunized with LVS DeltacapB i.n. or intradermally (i.d.) developed humoral and cellu

65 duced higher titers (1.63 +/- 0.25) than did i.n. immunization with NYVAC-HF (0.88 +/- 0.36; n = 9) a

66 ansmission, was modeled accurately by direct i.n. inoculation of Sendai virus at a low dose and low v

67 at received two immunizations with low doses i.n. (10 or 25 microg) of rNV VLPs and the majority of m

68 was aspirated into the lungs of mice during i.n. immunization and resulted in an acute inflammatory

69 tide conjugate proved to be a more effective i.n. IT reagent for protecting allergic mice from airway

70 .1-100 microgram) was administered by either i.n. or i.p. routes before OVA challenge in OVA-sensitiz

71 Furthermore, sIL-4R treatment by either i.n. or i.p. routes did not reduce airway hyperreactivit

72 c influenza virus infection following either i.n. or intraperitoneal inoculation.

73 CRs boosted with Ad5.RSV-F i.n. 28 days after an i.m. dose also had significant inc

74 Finally, i.n. immunization of C57BL/6 mice with either a recombin

75 Following i.n. challenge with nonlethal doses of H10407 and B7A, t

76 Following i.n. immunization, CD1, CD2, and CD4 induced significant

77 Following i.n. inoculation, latent DeltaM33B(T2) viral DNA was sig

78 s colonization and caries activity following i.n. immunization with GLU or Thio-GLU are attributed to

79 CD4+ T cells home to mouse brains following i.n. infection.

80 mmune responses to liposomal C-GTF following i.n. immunization.

81 t enhanced morbidity and mortality following i.n. MHV-1 infection compared to wild-type C3H/HeN mice.

82 ivated in the cervical lymph nodes following i.n. inoculation and then differentiated into Th17 cells

83 Transmission was more efficient from i.n.- than from i.p.-challenged gps, with 17% versus 83%

84 CVD 1203 given i.n. elicited high titers of antilipopolysaccharide (ant

85 However, i.n. inoculation of gnotobiotic pigs with 2/6-VLPs did n

86 Immunization i.n. with pneumococcal surface protein A (PspA) and IL-1

87 Animals immunized i.n. on days 0, 28, and 76 with bacterial vectors carryi

88 Animals immunized i.n. with OVA and CT were protected against tumor develo

89 Positive controls were immunized i.n. with C. trachomatis MoPn elementary bodies (EB).

90 we identified an attenuated and immunogenic i.n. vaccine candidate expressing GP from the pre-N posi

91 levels of IgG2a were four- sixfold higher in i.n.-immunized mice than in any of the other groups.

92 greater IgA Ab response in mucosal washes in i.n. immunized mice compared with SHIV VLPs.

93 MyD88(-/-) mice infected i.n. had higher numbers of CFU in the lungs as well as h

94 The initial i.n. dose-response with bacterial vectors alone identifi

95 o, only 14% (3/21) of the animals inoculated i.n. with Chlamydia had positive vaginal cultures.

96 unogenic in gnotobiotic pigs when inoculated i.n. and that the adjuvant mLT enhanced their immunogeni

97 Intranasal (i.n.) administration of a single dose of the H7N7 NL/03

98 Intranasal (i.n.) immunization of BALB/c mice with ntPEpilinPAK gene

99 Intranasal (i.n.) immunization of C57BL/6 mice with CT, CTA1-DD, LT,

100 Intranasal (i.n.) immunization of mice with CAT showed significantly

101 Intranasal (i.n.) immunization with bacterial protein antigens coupl

102 Intranasal (i.n.) infection of A/J mice with the CoV mouse hepatitis

103 Intranasal (i.n.) infections preferentially generate Th17 cells.

104 Intranasal (i.n.) inoculation of mice represents an experimental app

105 Intranasal (i.n.) inoculation of mice with the attenuated EHV-1 stra

106 ith wild-type C57BL/6 mice after intranasal (i.n.) and intravenous (i.v.) infection with live C. neof

107 les virus (MV) replication after intranasal (i.n.) challenge, this model can be used to assess the ef

108 rts of GI T cell responses after intranasal (i.n.) delivery of antigens that do not directly target t

109 body responses are induced after intranasal (i.n.) immunization of rHagB and if monophosphoryl lipid

110 rotection (80% survival) against intranasal (i.n.) challenge with ~240 median lethal doses (LD50) (2.

111 ignificant protection against an intranasal (i.n.) challenge as determined by the change in body weig

112 ce protection in mice against an intranasal (i.n.) challenge.

113 m of EBOV glycoprotein GP, as an intranasal (i.n.) EBOV vaccine.

114 tive immune responses through an intranasal (i.n.) route in mice.

115 ) not exposed to detergent as an intranasal (i.n.) vaccine.

116 both intraperitoneal (i.p.) and intranasal (i.n.) inoculation, M33 was attenuated for infection of t

117 ce sensitized to OVA by i.p. and intranasal (i.n.) routes are challenged with the allergen by i.n. ad

118 YR) and its Fab fragment (VN) by intranasal (i.n.) administration to infected SCID mice.

119 vaccination protocol followed by intranasal (i.n.) challenge of C57BL/6 mice with an equal number of

120 s type 1 (HIV-1) isolate 89.6 by intranasal (i.n.) immunization of mice with gp120 and gp140 together

121 cant immune responses in mice by intranasal (i.n.) immunization.

122 nicity induced in BALB/c mice by intranasal (i.n.) inoculation of enterotoxigenic Escherichia coli (E

123 In contrast, intranasal (i.n.) rAd immunization led to similarly robust local tra

124 Here, we found that following intranasal (i.n.) challenge, titers of virus in the lungs of the imm

125 the adult mouse model following intranasal (i.n.) immunization with fragments of VP6 and a subsequen

126 lymphoid tissue (NALT) following intranasal (i.n.) infections is investigated.

127 he lungs of WT animals following intranasal (i.n.) virus inoculation, while STAT1-/- mice developed a

128 al pneumonia, we show that local intranasal (i.n.) or systemic subcutaneous (s.c.) administration of

129 employed: intramuscular (i.m.), intranasal (i.n.) at a low dose and low volume, and i.n. at a high d

130 Following intramuscular (i.m.), intranasal (i.n.), or intravaginal (IVAG) immunization with VEE/SIN-

131 In neutropenic mice, intranasal (i.n.) doses of P. aeruginosa as low as 10 to 100 CFU/mou

132 ccine by either the oral (p.o.), intranasal (i.n.), or rectal route.

133 known concerning the efficacy of intranasal (i.n. ) administration of these antigens in inducing prot

134 A comparison of intranasal (i.n.) and parenteral immunization of BCG showed that whi

135 we investigated the efficacy of intranasal (i.n.) conjugate vaccine delivery using interleukin-12 (I

136 The protective potential of intranasal (i.n.) immunization with this chimeric immunogen was comp

137 s investigated following oral or intranasal (i.n.) administration of an aqueous adjuvant formulation

138 halitis following i.c., s.c., or intranasal (i.n.) challenge with the virulent VEEV ZPC738 strain (ZP

139 against an intradermal (i.d.) or intranasal (i.n.) challenge with vaccinia virus (vSC8) or a recombin

140 oneal cells after either i.p. or intranasal (i.n.) inoculation.

141 sponses in milk, while MVA prime/intranasal (i.n.) boost induced robust milk Env-specific IgA respons

142 vious study we demonstrated that intranasal (i.n.) vaccination promotes a Th17 biased immune response

143 ministered rLaSota/gp160 via the intranasal (i.n.) or intramuscular (i.m.) route in different prime-b

144 ministered to BALB/c mice by the intranasal (i.n.) route to evaluate the induction of mucosal antibod

145 vant, mice were immunized by the intranasal (i.n.) route with antigen alone or in conjunction with Fl

146 effect of immunizing mice by the intranasal (i.n.) route with Salmonella expressing an insoluble prot

147 ALB/c mice were immunized by the intranasal (i.n.) route with the surface protein adhesin AgI/II of S

148 Adult CD-1 mice infected by the intranasal (i.n.) route, showed that VEEV and WEEV enter the brain t

149 dose of HSV-2 strain 186 by the intranasal (i.n.) route.

150 ized mice, when delivered by the intranasal (i.n.) vs the intradermal (i.d.) route.

151 Mice that received three intranasal (i.n.) immunizations of H3N2 vaccine in the presence of L

152 tolerance induced by exposure to intranasal (i.n.) OVA and the subsequent development of AHR.

153 rotavirus (HRV), followed by two intranasal (i.n.) doses of a rotavirus-like particle (2/6-VLPs) vacc

154 overy and retained virulence via intranasal (i.n.) infection.

155 -G) was administered to mice via intranasal (i.n.), intramuscular (i.m.), and oral inoculation.

156 tivity following repeated weekly intranasal (i.n.) GSK2245035.

157 vaccination routes compared were intranasal (i.n.) and intradermal (i.d.) inoculation of the Francise

158 ; the 50% lethal dose (LD(50)) intranasally (i.n.) is >10,000-fold that of LVS.

159 vere disease when administered intranasally (i.n.) or intraperitoneally (i.p.).

160 ed CS constructs, administered intranasally (i.n.) or subcutaneously (s.c.), developed similar levels

161 livered subcutaneously (s.c.), intranasally (i.n.), i.m., or transcutaneously (t.c.).

162 nea pigs (gps) were challenged intranasally (i.n.) or intraperitoneally (i.p.) with 10,000 times the

163 ) lumen of a cohort challenged intranasally (i.n.) with S. pneumoniae type 6A, which is predominantly

164 cles (PorB VRP) were delivered intranasally (i.n.) or subcutaneously (s.c.) into the dorsal area or t

165 o Fcgamma receptors (FcgammaR) intranasally (i.n.) enhances immunogenicity and protection against int

166 binant priming delivered first intranasally (i.n.) plus orally and then intratracheally (i.t.), follo

167 When used as a vaccine given intranasally (i.n.), INA-inactivated influenza virus induced immune re

168 Animals were immunized intranasally (i.n.) and/or intramuscularly (i.m.) and subsequently cha

169 ve control group was immunized intranasally (i.n.) with 10(4) inclusion-forming units (IFU) of C. tra

170 BALB/c mice were immunized intranasally (i.n.) with gB DNA or DNA expressing beta-galactosidase (

171 nd C57BL/6 mice were immunized intranasally (i.n.) with peptides corresponding to a known CTL epitope

172 c lung response was similar in intranasally (i.n.) sensitized IL-10-/- and wild-type mice from a diff

173 In vivo, BALB/c mice intranasally (i.n.) treated with poly(I:C) (100 microg/mouse) 1 h befo

174 ested by infecting BALB/c mice intranasally (i.n.) with S. pneumoniae after i.n. administration of IL

175 zed intravaginally (i.vag.) or intranasally (i.n.) with a bacterial protein antigen (AgI/II of Strept

176 fected intradermally (i.d.) or intranasally (i.n.) with LVS succumbed to infection with doses 2 log u

177 ize CD4 KO mice either i.p. or intranasally (i.n.).

178 mice, orogastrically (o.g.) or intranasally (i.n.).

179 ministered to gnotobiotic pigs intranasally (i.n.) with a mutant Escherichia coli heat-labile toxin,

180 a virus infection to show that intranasally (i.n.) primed memory CD8+ T cells possess a unique abilit

181 nfected intravaginally (i.v.), intranasally (i.n.), orally (p.o.), or subcutaneously (s.c.) with C. t

182 antibody that were vaccinated intranasally (i.n.) developed lower neutralizing titers, with NYVAC-HF

183 BALB/c mice vaccinated intranasally (i.n.) with KKF24 and subsequently challenged with wild-t

184 nterleukin-12 (IL-12) delivered intransally (i.n.) as an antiviral respiratory adjuvant.

185 econdary challenge but not high doses of LVS i.n. challenge, independently of the route of vaccinatio

186 4 or 8 weeks later with a lethal dose of LVS i.n., they were 100% protected from illness and death an

187 nt than protein boosting by either the i.m., i.n., or t.c. route, suggesting that this route may be p

188 Thus, maternal i.n./i.m. combined immunization is a novel strategy to e

189 In mice i.n. challenged with B7A, low serum IgG antibody titers

190 In mice i.n. challenged with H10407, serum immunoglobulin G (IgG

191 la tularensis (iFT) organisms to FcR in mice i.n., with MAb-iFT immune complexes, enhances F. tularen

192 Ure (25 microg p.o. or rectally or 10 microg i.n.) plus heat-labile toxin from Escherichia coli as th

193 mol, i.n.) prevented iron-induced (4.2 nmol, i.n.) oxidative stress and nigral injury, reflected by a

194 usion of freshly prepared GSNO (0-16.8 nmol, i.n.) prevented iron-induced (4.2 nmol, i.n.) oxidative

195 n vitro, T cells from the superficial CLN of i.n. immunized mice secreted both gamma interferon and i

196 In this study, we examined the effects of i.n. IL-12 treatment on induction of protective humoral

197 This indicated that our procedure of i.n. administration of Ab did not make optimal use of th

198 differentiation of mass spectral profiles of i.n.-inoculated mouse lung tissues from those of i.d.-in

199 resulting in the preferential recruitment of i.n.-primed memory CD8+ T cells to the lung airways.

200 The resistance of i.n.-immunized mice (and to some extent the i.v.-exposed

201 Our studies demonstrate the superiority of i.n. versus i.m. vaccination in protection against both

202 ype 3 pneumococci, there was 75% survival of i.n. vaccinated mice compared to 0% survival of unvaccin

203 Thus, the tendency of i.n. infection to induce Th17 cells is related to cytoki

204 of priming (intraperitoneal) followed by one i.n. challenge we found that IL-10-/- C57BL/6 mice had h

205 parable T cell responses in the spleen, only i.n. delivery elicited specific T cell responses in the

206 profiles in Th2-sensitized mice, while only i.n. IT had significant immunomodulatory activity on B a

207 ither one or both antigens by either s.c. or i.n. administration.

208 ion of CT compared to i.n. or i.m. gB DNA or i.n. live HSV immunization.

209 tears and serum of guinea pigs after o.g. or i.n. immunization, the i.n. route elicited significantly

210 ties distinct from those elicited by i.m. or i.n. rAd immunization.

211 CRs vaccinated with Ad5.RSV-F given i.m. or i.n., and these responses correlated with reduced replic

212 In animal models of type 1 diabetes, oral or i.n. immunization with islet antigens induces Tregs that

213 onorrhoeae recombinant porin B (Ng-rPorB) or i.n. with Eagle's minimal essential medium (MEM-0).

214 and control C3H/HeOuJ mice following i.v. or i.n. challenge with C. neoformans.

215 en administered at higher doses by the oral, i.n., and i.p. routes than the wild-type strain even tho

216 Overall, i.n. administration of ntPEpilinPAK induced mucosal and

217 tide inhibitor of PAR2 signalling, pepducin, i.n. before allergen challenges and then assessed AHR an

218 ungs was consistently detected by day 6 post-i.n. challenge for the immunized mice and by day 14 for

219 At day 7 postinfection, i.n.- and i.v.-immunized mice had high levels of chlamyd

220 mals previously immunized with the MVA prime/i.n. boost regimen received an i.n./i.m. combined C.1086

221 o 10-fold-higher doses of NOMV were required i.n. compared to i.p. to elicit an equivalent bactericid

222 on day 28, a single intranasal challenge (s.i.n.) with either OVA or ragweed.

223 Eight hours after the s.i.n., BAL fluid was obtained.

224 Mice receiving a second i.n. immunization with liposomal antigen and MPL-AF had

225 A single i.n. inoculation with KyA induced protective immunity ag

226 Moreover, a single i.n. or IVAG immunization with VEE/SIN-Gag induced a lar

227 Specifically, i.n. or s.c. administration of c-di-GMP 48 and 24 h prio

228 tended these studies to compare the standard i.n./i.t. regimen with additional mucosal administration

229 ual antigen can be corrected by a subsequent i.n. virus infection.

230 sponse that is protective against subsequent i.n. challenge with the wild-type strain.

231 o elicit mucosal antibody responses and that i.n. immunization resulted in increased total, immunoglo

232 Collectively, the results demonstrate that i.n. vaccination with KKF24 induces a vigorous Th1-type

233 Our results indicate that i.n. and possibly even oral delivery of live Salmonella

234 These results indicate that i.n. delivery of meningococcal NOMV in mice is highly ef

235 This study indicates that i.n. immunization with both PMT and CN induces an effect

236 l and immunohistochemical findings show that i.n.-infected gps display enhanced lung pathology and EB

237 estigations may be the first to suggest that i.n. IT is more effective than i.d. IT for the treatment

238 The results suggest that i.n.-challenged gps are more infectious to naive animals

239 The i.n. administration of 100 microgram sIL-4R before aller

240 The i.n. delivery of rNV VLPs was more effective than the or

241 The i.n. immunization induced predominantly IgA antibody-sec

242 The i.n. inoculation of BALB/c mice with large doses of ETEC

243 After the i.n. challenge mice immunized with MOMP, CpG, and alum s

244 l responses of female mice given VLPs by the i.n. and oral routes were also examined.

245 soluble proteins when coadministered by the i.n. or oral route.

246 Mice immunized by the i.n. route had higher levels of salivary, plasma, and va

247 ce given AgI/II with LT-IIa or LT-IIb by the i.n. route had significantly higher mucosal and systemic

248 B7-1, B7-2, and B7-1/2 knockout mice by the i.n. route revealed that the ability of FljB to increase

249 Priming by the i.n. route was more immunogenic than by the i.m. route,

250 .v. 70 days later, animals preexposed by the i.n. route were highly resistant to reinfection, with gr

251 Mice immunized by the i.n. route with antigen and FljB exhibited significantly

252 ctivity was highest in mice immunized by the i.n. route with antigen formulations containing MPL-AF (

253 unized three times (2-week intervals) by the i.n. route with HagB (20 microg) alone or with MPL (25 m

254 eived phosphate-buffered saline alone by the i.n. route.

255 ea pigs after o.g. or i.n. immunization, the i.n. route elicited significantly higher antibody titers

256 sma IgA and plasma IgG, respectively (in the i.n. immunized groups).

257 urvival was also significantly better in the i.n.-parenteral group (3 of 9) than in the other HF-vacc

258 These studies indicate that the i.n. challenge of BALB/c mice with ETEC strains may prov

259 sease, we found similar results by using the i.n. and intraperitoneal (i.p.) routes of inoculation fo

260 Importantly, immunization via the i.n. but not the s.c. route elicited sporozoite neutrali

261 Two or three immunizations via the i.n. or i.m. route induced a more potent systemic and mu

262 or 100% protection when administered via the i.n. route.

263 Therefore, i.n. immunization is a potential delivery route of choic

264 Three i.n. doses of gB DNA over a 3-week period resulted in a

265 doses of attenuated Wa HRV (AttHRV3x), three i.n. doses of 2/6-VLPs plus mLT (VLP3x), three i.n. dose

266 n. doses of 2/6-VLPs plus mLT (VLP3x), three i.n. doses of purified double-layered inactivated Wa HRV

267 tional i.n. administration of CT compared to i.n. or i.m. gB DNA or i.n. live HSV immunization.

268 to OVA was crucial, because mice exposed to i.n. OVA 15-30 days after viral inoculation developed ne

269 A abrogated tolerance induced by exposure to i.n. OVA, and instead led to the development of AHR acco

270 i.m. inoculation was inferior to i.n. inoculation at inducing antibody responses and prot

271 t that infant ferrets are less responsive to i.n. vaccination than are older ferrets and raises quest

272 nd subsequently challenged with RSV/A/Tracy (i.n.) to assess protection.

273 wing aerosol challenge with M. tuberculosis, i.n. boosting of BCG with either BCG or M.85A afforded u

274 For the second regimen (VLP2x/AttHRV), two i.n. doses of 2/6-VLPs+mLT were given, followed by one o

275 Of the animals vaccinated i.n. with the Chlamydia, 81% (17/21) had embryos in both

276 Rabbits vaccinated i.n. had significant nasal and bronchoalveolar lavage Ig

277 n vaccinated mice challenged with ZPC738 via i.n. or i.c. route, we regularly detected high levels of

278 High-dose, high-volume i.n. inoculation resulted in the highest levels of antib

279 Low-dose, low-volume i.n. inoculation afforded complete protection from conta

280 Weekly i.n. GSK2245035 20 ng was well tolerated and reduced all

281 When mice were i.n. challenged 4 months after the last boost, titers of

282 Mice that were i.n. administered H3N2 vaccine alone, without LT(R192G),

283 lungs and the CLN of animals immunized with i.n. administered beta-Gal DNA.

284 n G (IgG) and Fab cleared the infection with i.n. 50% effective doses (ED(50)s) of 16 and 90 pmol, re